Speech by Federal Chancellor Dr. Angela Merkel at the inauguration of the new laboratory building of the Robert Koch Institute on February 3, 2015, in Berlin:

Germany Angela Merkel · Former Chancellor of Germany

3 February 2015 · Inauguration of the new laboratory building of the Robert Koch Institute · Robert Koch Institute, Berlin, Germany

Context
Merkel addressed staff and guests at the inauguration of the Robert Koch Institute's new laboratory building in Berlin on February 3, 2015.
Main themes
Robert Koch Institute, infectious disease research, new laboratory building inauguration, high-security S4 laboratory, Ebola virus research, biomedical research, public health infrastructure, disease monitoring and prevention, international health cooperation, scientific excellence, federal health policy
Duration
~19 min
62nd percentile
Words
2,226
62nd percentile
Sentences
138
77th percentile
Readability
47
53rd percentile
Grade
10.7
29th percentile
Syntax
2.79
21st percentile
Vocabulary
2.09
24th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 59%59%
  • Ceremonial 23%23%
  • Institutional 9%9%
  • Economic 4%4%
  • Geopolitical 3%3%
  • Technological 1%1%
  • Environmental 0%0%
  • Not in focus 1%

138 sentences in 40 paragraphs

Dear Professor Burger,

Dear Federal Minister, dear Ms. Hendricks,

Dear Federal Minister, dear Hermann Gröhe,

Dear colleagues from the German Bundestag,

Mr. Vice President of the German Bundestag,

and above all, you, dear employees of the Robert Koch Institute and esteemed guests – some of you can also follow our event on the screen; I warmly welcome you as well!

I am pleased to be here today as we open this new building with the highest possible standards. Top-level research requires top-level conditions – this was true even in Robert Koch's time. Many of his groundbreaking insights were also thanks to technical innovations. And it is still true today. Therefore, I am very pleased that with the state-of-the-art laboratory building of the Robert Koch Institute, we now have the best conditions for further gaining insights and achieving progress as a result of these insights.

Realizing such a building – on this scale, with these high safety requirements in the middle of Germany's largest city – is a masterpiece. – Professor Burger has already given us an insight into the highs and lows of the construction history. – Therefore, I say: Great respect is due to all who contributed to this. We also say in German: All's well that ends well. The operating permit may still be pending, but the building now stands completed.

Together with the two ministers, I already had the opportunity to take a tour. The building complex is very impressive. This is especially true, of course, for the high-security laboratory. Hermetically sealed, access only through a complex sluice system, its own air, electricity, and water supply – in view of all these safety precautions, one could speak of a kind of Fort Knox of the RKI. Although no gold is stored here, the insights that will be gained here in the future could be worth gold. Here are excellent conditions for research on highly pathogenic pathogens such as Ebola viruses. It is no coincidence that the Federal Government's Special Envoy for Ebola, Ambassador Lindner, is also here today.

Of course, even the best facility is only as valuable as it is actually used. Therefore, I am pleased with the institute about a personnel reinforcement. In addition to the already known excellent staff, there is also additional personnel. With the modern S4 laboratory, the RKI has a special trump card in its hand to attract new scientists who specialize in working with dangerous pathogens. I think they will find very attractive working conditions here. I want to thank everyone who specializes in such work. When you hear about it from the outside, you realize that it is not entirely without danger. All the more important is that we can say: Here, there are truly excellent conditions for this work.

The new building as a whole will further advance application-oriented biomedical research as one of the core tasks of the Robert Koch Institute. This will give the institute an even more important role in the fight against infectious diseases than it already has today. It has already been mentioned that the amount that had to be invested is not insignificant. I want to reveal the secret: The investments of around 170 million euros are – we are convinced – well invested.

The Robert Koch Institute is a central federal institution in the field of disease monitoring and prevention. When new diseases occur or diseases spread very quickly, the question immediately arises: Well, you will surely have everything available that is technically and medically feasible. If one had to answer, "We are just in the middle of construction" or "We are not that far yet," then understanding would be low in such moments. Fortunately, there are also long periods when not much is in demand. But when something happens, you want quick and absolutely precise answers.

This facility is an early warning system for new health risks. It is a control center when diseases break out and health authorities need support. It is a kind of competence center for advice at the federal and state level as well as for clinics and laboratories. The federal institute also enjoys an excellent international reputation. It supports, both in personnel and with its expertise, at the European and international level, for example, the European Centre for Disease Prevention and Control, the World Health Organization, which also urgently relies on the latest insights, and numerous research collaborations. This means: When it comes to recognizing, preventing, and combating infectious diseases, the Robert Koch Institute is an important contact – an excellent address both nationally and internationally.

Dear Professor Burger, that this is the case is also personally attributable to you. This is not a farewell speech, as your official farewell is still pending. But I would like to take this opportunity to sincerely thank you. You have played a major role in the successes of the Robert Koch Institute. The fact that this construction project was realized at all has much to do with your long-standing commitment, but also with that of your predecessors – you have already pointed this out.

Of course, even with expanded capacities, research successes cannot simply be planned or predicted – that is the nature of research. But one can say: Successes become more likely when one is well-equipped. How important – vital in the truest sense of the word – biomedical research is, is best shown in comparison with the past. Many infectious diseases that were once commonplace here have now lost their terror – tuberculosis, for example, a disease particularly associated with the name Robert Koch. Improved hygiene, vaccinations, or therapies have made many life-threatening diseases manageable risks for us. But we must ensure that knowledge benefits as many people as possible worldwide. We are still far from that. We must also ensure that we remain vigilant. Because some diseases, which were considered no longer existent, can still spread again in other regions of the world.

It is estimated that today around 1.5 million children worldwide still die each year from diseases that could be prevented by vaccination. This sad record challenges us to act. Last week, Berlin hosted the conference of the global vaccine alliance GAVI. Representatives from many countries came to replenish the fund for global vaccination programs. The set goal of raising 7.5 billion US dollars for the period from 2016 to 2020 was achieved – with new financing instruments, it is even almost ten billion US dollars. This will allow us to vaccinate many millions of children in the coming years. We have set ourselves the goal of being able to vaccinate at least 300 million children again and thus significantly reduce child mortality. The presidents from Tanzania and Mali, Mr. Kikwete and Mr. Keita, who were present, told very vividly what this means for the children in their countries. It touches so many individual fates.

The conference was a successful start for our health policy engagement within the framework of the German G7 presidency. In addition to better vaccination protection for children, we also want to address the handling of antimicrobial resistance. The problem of antibiotic resistance of pathogens has massively increased in recent years. This applies not only to developing countries but also to industrialized countries. In Germany, many patients have to experience that they are infected with pathogens against which conventional antibiotics are unfortunately powerless.

It is good that we have already made progress here with the help of the German Antibiotic Resistance Strategy – again thanks to the efforts of the Robert Koch Institute. We were able to initiate some important measures; for example, for improved hospital hygiene – this remains a task for the future – and also with regard to the use of antibiotics in animal husbandry – this topic also remains on the agenda. We have also gained valuable experience in monitoring the development of antibiotic consumption and antibiotic resistance. We want to build on this and share these experiences internationally.

The World Health Assembly in May of this year is expected to adopt the first global action plan to combat antimicrobial resistance; I will also visit the World Health Organization. We want to build on the insights and decisions at our G7 summit at the beginning of June. We should take the opportunity to agree on a common approach to achieve concrete improvements. Because tackling antimicrobial resistance is a collective task. Many countries would be overwhelmed by it alone.

This also applies with regard to diseases that the World Health Organization counts among the neglected tropical diseases. Around one billion people worldwide suffer from them, mostly belonging to the poorest population groups. If I understand correctly, these diseases are referred to as "neglected" because they are not highly contagious and hardly reach us in industrialized countries. But one billion people – that is a dramatically high number.

Comparatively highly developed countries, on the other hand, can consider themselves fortunate that these diseases are almost no issue for them. However, this results in a lack of research incentives and the development of diagnostic tests, therapies, and vaccines is not very advanced. A change in thinking is urgently needed here. We want to address this issue, without believing that we can adequately address it during our G7 presidency.

The Ebola epidemic in West Africa has shown us the consequences of uncontrolled outbreaks of infectious diseases. Thousands have been infected and have died. The human suffering, social upheavals, and economic damage are immeasurable. Therefore, we are called upon in the short term to continue our emergency aid in the affected countries. Germany is doing this.

I would like to expressly thank all the employees of the Robert Koch Institute who have agreed to analyze blood samples in West Africa and train medical personnel. I also thank everyone who ensures that Germany is well prepared for the challenges that Ebola brings. We have made the necessary arrangements with the centers.

In the long term, however, we must also better prepare ourselves worldwide against the outbreak of such infectious diseases. Therefore, it will be very important that we jointly draw lessons from what we have experienced in connection with Ebola. There are already proposals for this. Now it is a matter of bundling and analyzing these proposals to develop realistic options for concrete improvements. Therefore, I have joined with the Prime Minister of the Kingdom of Norway and the President of Ghana in addressing the Secretary-General of the United Nations, Ban Ki-moon. I believe he is the right address when it comes to commissioning a report with concrete improvement proposals.

In this initiative, I am particularly concerned with six points that we should keep in mind.

First

: We need a sufficient number of doctors and medical personnel who are ready for deployment at any time and can be quickly deployed in crisis areas – so to speak, white helmets. Speed is a crucial factor. We have already seen this with Ebola. Ebola is one of the contagious diseases, but not one of the most contagious diseases. There are diseases where the spread on a global scale could proceed much faster. Therefore, it is important to take precautions.

Second

: In addition to personnel, equipment and materials – field hospitals, mobile laboratories, and so on – must reach the affected region as quickly as possible. This means we need efficient logistics.

Third

: Because all this costs money, we need to establish a fund to quickly access financial resources. The President of the World Bank also pointed this out at the G20 meeting.

Fourth

: Suitable organizational structures of the United Nations are needed so that they can fulfill their steering and coordination function in the event of an epidemic.

Fifth

: The health systems in particularly threatened states must be strengthened. This is a permanent task. It was evident that particularly fragile health systems contributed to the fact that three West African countries were very strongly affected by Ebola.

Sixth

We need more incentives for the research and production of drugs and vaccines against neglected diseases. In this regard, hopes are naturally also directed towards Germany in general and, as always, towards the Robert Koch Institute in particular.

Whether for prevention or response, with the new high-security laboratory, we are well-equipped to handle highly pathogenic disease agents. The location also proves to be an advantage. As Professor Burger has already mentioned, the high-security laboratory is in close proximity to the special isolation unit of the Virchow Clinic. Therefore, in an emergency, when every minute counts, the time lost due to elaborate secured transports is minimized. Especially with highly contagious diseases, speed is crucial, as I have already mentioned.

You don't have to be a scientist to see, using the example of the Robert Koch Institute, what a great benefit top-level research can be. What you do here serves the well-being of everyone. For this, you deserve not only thanks and recognition, but you have also truly earned this new building. The German Bundestag has also supported you vigorously.

For your extremely valuable and probably very exciting work for many, I wish you continued success—and if you have that, it will be for the benefit of us all; then many people will be better off. Thank you for allowing me to be here today. Enjoy your work, have fun, make good discoveries, and foster good international cooperation!